Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Wonjun Ji
Mechanisms of Acquired Resistance to EGFR-tyrosine Kinase Inhibitor in Korean Patients With Lung Cancer
BMC Cancer
Cancer Research
Oncology
Genetics
Sex Differences of COPD Phenotypes in Nonsmoking Patients
International Journal of COPD
Environmental
Public Health
Health Policy
Medicine
Pulmonary
Respiratory Medicine
Occupational Health
Related publications
Elucidating the Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer Patients
Canadian Journal of Biotechnology
Glucosylated Epigallocatechin Gallate (EGCG) Derivatives Combined With EGFR Tyrosine Kinase Inhibitor Overcome Resistance in EGFR T790M Mutant Lung Cancer
Biomedical Journal of Scientific & Technical Research
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
JAMA Oncology
Cancer Research
Oncology
P1.13-23 TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Phase 1 Trial of Dasatinib Combined With Afatinib for Epidermal Growth Factor Receptor- (EGFR-) Mutated Lung Cancer With Acquired Tyrosine Kinase Inhibitor (TKI) Resistance
British Journal of Cancer
Cancer Research
Oncology
Squamous Cell Transformation and EGFR T790M Mutation as Acquired Resistance Mechanisms in a Patient With Lung Adenocarcinoma Treated With a Tyrosine Kinase Inhibitor: A Case Report
Oncology Letters
Cancer Research
Oncology
Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor
OncoTargets and Therapy
Oncology
Pharmacology
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
